基因导向"反核导弹"癌症治疗中的甲素B核流
Fei Cao1, Caroline Tang1, Xiaoyong Chen1
1Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut 06510, United States.
ACS central science
|September 2, 2024
概括
抗核抗体 (ANA) 可以进入癌细胞并诱导核变化. 研究人员设计了一种抗核抗体-药物联合体 (ANADC) 用于瘤无关癌症治疗,作为DNA寻找导弹.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 抗核抗体 (ANA) 可以与瘤微环境中的细胞外核酸相互作用.
- 这些核酸通过核酸救援途径被活癌细胞内化,独立于表面抗原.
研究的目的:
- 调查ANA核透的机制及其后果.
- 开发一种新型抗体-药物联合体 (ANADC) 用于利用这种机制进行癌症治疗.
主要方法:
- 研究了ANA核入口及其对核完整性的影响.
- 设计了一个使用甲素B-labile链接器的NADC.
- 评估了ANADC针对死瘤中核酸残渣的目标.
主要成果:
- 已被证明,ANA核透会诱导由甲素B介导的核流.
- ANADC成功地准了细胞外核酸,并进入了癌细胞.
- ANADC展示了作为一种瘤不可知治疗方法的潜力.
结论:
- ANA核透是一种可行的机制,可以向癌细胞输送有效载荷.
- ANADCs代表了一类有前途的新型癌症治疗药物.
- 这种方法提供了一种针对癌症的瘤无知策略,通过核酸救援途径向癌症.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K


